Sonidegib

Sonidegib (INN; also known as LDE225 and erismodegib; trade name Odomzo) is a Hedgehog signaling pathway inhibitor (via smoothened antagonism) being developed as an anticancer agent by Novartis.RET inhibitors: Vandetanib (also VEGFR and EGFR). Entrectinib (ALK, ROS1, NTRK).c-MET inhibitor: Cabozantinib (also VEGFR2). Sonidegib (INN; also known as LDE225 and erismodegib; trade name Odomzo) is a Hedgehog signaling pathway inhibitor (via smoothened antagonism) being developed as an anticancer agent by Novartis. It was approved by the FDA for treating basal-cell carcinoma in July 2015 and is awaiting approval in the EU. In the EU, the agent has received positive opinion from the CHMP for approval. It is indicated for the treatment of adult patients with locally advanced basal-cell carcinoma that has recurred following surgery or radiation therapy, or those who are not candidates for surgery or radiation therapy. Sonidegib is administered orally. Common side effects include muscle spasms, hair loss, fatigue, abdominal pain, nausea, headache, and weight loss. Sonidegib binds to and inhibits smoothened to inhibit activation of the Hedgehog pathway. Sonidegib is primarily metabolized by CYP3A and is eliminated hepatically.